Trial Profile
A Phase I Study of the Reduced Immunogenicity Mesothelin-Targeted Immunotoxin LMB-100 in Patients With Malignant Mesothelioma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Aug 2022
Price :
$35
*
At a glance
- Drugs LMB 100 (Primary) ; Paclitaxel
- Indications Carcinoma; Malignant-mesothelioma
- Focus Adverse reactions
- 22 Jan 2021 Status changed from active, no longer recruiting to completed.
- 01 Sep 2020 The protocol was amended to allow intrapatient dose de-escalation so that these patients were able to receive cycle 2 of therapy at a dose of 140 µg/kg without any DLT.
- 01 Sep 2020 Results published in the Cancer